Leveraging his experience as an entrepreneur and building off of his desire to impact the mental health crisis, Dick co-founded Sensorium Therapeutics in 2021 with leading researchers and clinicians at Harvard and Massachusetts General Hospital. Sensorium was founded to translate insights from nature into transformational therapeutics, integrating centuries of ethnobotanical insight about plants and their therapeutic uses into a modern drug discovery context.
Since its founding in 2021, Sensorium has:
Developed a drug discovery platform to systematically identify and refine drug candidates inspired by natural products with a history of human use. The platform leverages proprietary artificial intelligence/machine learning tools integrated with high throughput screening activities conducted at Sensorium’s lab.
Advanced candidates towards the clinic, including SENS-01 to impact anxiety.
Raised $31 million in venture financing from partners including Santé Ventures, Route 66 Capital, CU Innovation Fund, Palo Santo, Iter Investments, WPSS and others.
Been awarded $3mm from the US National Institute of Health to explore compounds in additional disease areas.
Assembled a team of 20+ scientists and business leaders in Boston and around the United States.
Dick served as CEO of Sensorium until December 2023 before bringing Sandra Glucksmann, PhD, into the company to spearhead its next phase of growth. He continues to serve as an active Founder, Board Member, and Advisor to the company.